Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension-Reference-Cited by-同舟云学术

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension

Published:2019-04-08 Issue:1 Volume:286 Page:63-74
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Bringhen S.¹^ORCID,Milan A.²,D'Agostino M.¹,Ferri C.³,Wäsch R.⁴,Gay F.¹,Larocca A.¹,Offidani M.⁵,Zweegman S.⁶,Terpos E.⁷,Goldschmidt H.⁸,Cavo M.⁹,Ludwig H.¹⁰,Driessen C.¹¹,Auner H. W.¹²,Caers J.¹³,Gramatzki M.¹⁴,Dimopoulos M. A.⁷,Boccadoro M.¹,Einsele H.¹⁵,Sonneveld P.¹⁶,Engelhardt M.⁴

Affiliation:

1. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero‐Universitaria Città della Salute e della Scienza di TorinoUniversity of Torino Torino Italy

2. Department of Medical Sciences, Internal Medicine and Hypertension Division, AOU Città della Salute e della Scienza di Torino, Rete Oncologica Piemontese University of Torino Torino Italy

3. University of L'Aquila, MeSVA Department ‐ San Salvatore Hospital Division of Internal Medicine & Nephrology Coppito Italy

4. Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center – University of Freiburg, Faculty of Medicine University of Freiburg Freiburg Germany

5. Clinica di Ematologia AOU Ospedali Riuniti di Ancona Ancona Italy

6. Amsterdam UMC, Vrije Universiteit Amsterdam, VU University Medical Center, Department of Hematology Cancer Center Amsterdam Amsterdam the Netherlands

7. Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece

8. University Clinic Heidelberg Internal Medicine V and National Center for Tumor Diseases (NCT) Heidelberg Germany

9. ‘Seràgnoli’ Institute of Hematology and Medical Oncology University of Bologna Bologna Italy

10. 1. Medical Department and Oncology Wilhelminenspital Wien Vienna Austria

11. Department of Oncology and Hematology Kantonsspital St. Gallen St. Gallen Switzerland

12. Faculty of Medicine, Department of Medicine Imperial College London London UK

13. Department of Hematology Domaine University Liege Liege Belgium

14. Division of Stem Cell Transplantation and Immunotherapy University of Kiel KielGermany

15. Department of Internal Medicine II University Hospital Würzburg Würzburg Germany

16. Department of Hematology Erasmus Medical Center Rotterdam the Netherlands

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.12882

Reference36 articles.

1. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

2. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

3. Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

4. Carfilzomib-Associated Cardiovascular Adverse Events

5. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Strategies in Immune Modulation and Desensitization Protocols;Textbook of Transplantation and Mechanical Support for End‐Stage Heart and Lung Disease;2023-09-08

2. Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network;Frontiers in Oncology;2023-04-25

3. Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience;Cancers;2023-02-10

4. Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study;Cancers;2023-02-02

5. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies;JACC: CardioOncology;2023-02